Close Menu

Prostate Cancer

News and reporting on prostate cancer.

Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.

Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.

Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.

Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.

The researchers used 10X Genomics' linked-read genome sequencing approach to home in on rearrangements that affect the androgen receptor locus and its enhancer.

Using data for more than 140,000 individuals, researchers narrowed in on 63 new prostate cancer-associated loci and established a polygenic score linked to enhanced risk.

A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.

The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.

Exome sequencing on tumors from metastatic, castration-resistant prostate cancer cases responding to immunotherapy led to homologous recombination defects.

In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.